A simple blood test is able to identify the molecular signature That predice The physical and cognitive decline in the elderlydistinguishing the subjects already fragile from those found in one Intermediate state between health and fragility: It is the result obtained by the Italian study published in the magazine NPJ aging, led by the Ceinge Biotechnology Laboratory Advanced Franco Salvatore of Naples, the University of Campania Luigi Vanvitelli and the University of Pavia.
The research, which also participated in the University of Salerno, the IRCCS Foundation from Mondino di Pavia and the Federico II University of Naples, then opens new perspectives For therapies That, If administered at the key moment of passage identified by the testcould slow down or even reverse the process, allowing you to age in good health.
In particular, the researchers coordinated by Alessandro Usiello of Ceinge and University Luigi Vanvitelli and by Enza Maria Valente of the University of Pavia and the Mondino Foundation, found that the people so -called ‘pre-small‘, which are found precisely in critical moment of passageshow higher levels Of betaine Both compared to healthy and fragile subjects. Betain is one molecule that protects cells from stressfrom the dehydrationfromexcessive salinity and plays an important role also in Reduction of the risk of cardiovascular diseases.
“Betaine contributes to maintaining low the levels Of homocysteinewhich when elevated involve an increase in cardiovascular risk“, says Usiello.” I next steps The biological mechanisms responsible for the variations that emerged in the study will be investigated – adds the researcher – and verify whether the supplementation of betaine or specific formulations can represent a possible therapeutic strategy to promote a healthy aging “.
Reserved reproduction © Copyright Ansa
Source: Ansa
I am a journalist with over 6 years of experience working in the news industry. I currently work as an author for Global Happenings, and my coverage focuses on Technology news. I have written for various publications, including Reuters, The New York Times and The Guardian.
